Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy

NCT02460094 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02460094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02460094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Completed
Start date
October 2, 2015
Completion date
October 19, 2016
Enrollment
48 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

progressive supranuclear palsy